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Abstract.  
Objectives – Platelet endothelial cell adhesion molecule-1 (PECAM-1) regulates platelet 
response to multiple agonists.  How this immunoreceptor tyrosine-based inhibitory motif–
containing receptor inhibits G protein-coupled receptor–mediated thrombin-induced 
activation of platelets is unknown.   
Approach and Results – Here, we show that the activation of PECAM-1 inhibits fibrinogen 
binding to integrin αIIbβ3 and P-selectin surface expression in response to thrombin (0.1–
3U/ml) but not thrombin receptor-activating peptides SFLLRN (3x10-7–1x10-5M) and 
GYPGQV (3x10-6–1x10-4M). We hypothesised a role for PECAM-1 in reducing the tethering 
of thrombin to GPIbα on the platelet surface.  We show that PECAM-1 signalling regulates 
the binding of FITC-labelled thrombin to the platelet surface and reduces the levels of cell 
surface GPIbα by promoting its internalisation, while concomitantly reducing the binding of 
platelets to von Willebrand factor under flow in vitro.  PECAM-1 mediated internalisation of 
GPIbα was reduced in the presence of both EGTA, and/or Cytochalasin D and Latruculin, 
but not either individually, and was reduced in mice in which tyrosines 747 and 759 of the 
cytoplasmic tail of β3 integrin were mutated to phenylalanine.  Furthermore PECAM-1 cross-
linking led to a significant reduction in the phosphorylation of GSK-3β Ser9, but interestingly 
an increase in GSK-3α pSer21. PECAM-1 mediated internalisation of GPIbα was reduced by 
inhibitors of Dynamin (Dynasore) and GSK-3 (CHIR99021), an effect that was enhanced in 
the presence of EGTA.  
Conclusions – PECAM-1 mediates internalisation of GPIbα in platelets through dual 
AKT/AKT/protein kinase B/glycogen synthase kinase-3/dynamin-dependent and αIIbβ3-
dependent mechanisms. These findings expand our understanding of how PECAM-1 
regulates non-immunoreceptor signalling pathways and helps to explains how PECAM-1 
regulates thrombosis. 
 
 
 
 
Nonstandard abbreviations and acronyms 
PMI PECAM-1 mediated internalisation 
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Introduction 
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a 130-kDa transmembrane 
glycoprotein expressed on the platelet surface at between 5000 and 8800 copies per cell.1-3  
It is composed of a 574 amino acid residue extracellular portion organised into six 
immunoglobulin (Ig)-like homology domains, a 19 amino acid transmembrane domain and a 
cytoplasmic domain that contains an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) 
((L/V/I/S/T)XYXX(L/V)) and an Immunoreceptor Tyrosine-based Switch Motif (ITSM) 
(TxYxx(V/I)).4, 5 The tyrosine residues (residues 663 and 686) within the ITIM and ITSM 
become tyrosine phosphorylated by Src or Csk family kinases,6 following homophilic ligation 
or stimulation of platelets through protease-activated receptor (PAR)-1 and 4, glycoprotein VI 
(GPVI), or GPIb in a process that is largely, but not wholly, dependent on integrin αIIbβ3-
dependent platelet aggregation.7-10   
The inhibition by PECAM-1 of immunoreceptor signalling downstream of GPVI is well 
established. Once phosphorylated these twin ITIM and ITSM tyrosine residues support the 
recruitment of Src-homology 2 (SH2) domain containing proteins, including the protein-
tyrosine phosphatases SHP-2, and to a lesser extent SHP-1,11 to which the p85 regulatory 
subunit of phosphatidylinositol 3-kinase (PI3-K) becomes associated destabilising its 
association with the linker for activation of T cells (LAT) and the scaffolding molecule Grb-2-
associated binding protein-1 (Gab1).12  By disturbing the LAT-GAB1-PI3K signalling complex 
PECAM-1, therefore, disrupts the recruitment and activation of phospholipase C (PLCɣ2),12 
thereby inhibiting immune-like signalling downstream of GPVI and reducing the activation of 
platelets by collagen, the GPVI specific ligand cross-linked collagen-related peptide (CRP-
XL) and convulxin (CVX).10, 13, 14 
More surprising is the ability of PECAM-1 to reduce platelet activation through GPCR 
mediated signalling pathways following stimulation by thrombin or ADP.  Whilst hyper-
reactivity to thrombin and ADP has not been detected in PECAM-1 deficient mice,15 pre-
activation of PECAM-1 has been shown to reduce fibrinogen binding to platelets, secretion 
and calcium mobilisation in response to ADP and thrombin,14 and in a laser injury model of 
thrombosis in cremaster muscle arterioles, that is dependent on thrombin generation rather 
than collagen exposure,16 thrombi formed more rapidly, were more stable and approximately 
35% larger in PECAM-1 deficient mice.17 The mechanism by which PECAM-1 inhibits 
GPCR-mediated activation of platelets is as yet unclear. 
While the inhibitory effect of PECAM-1 on individual pathways is modest, corresponding to 5-
15% inhibition in platelet function, the physiological importance of PECAM-1 comes from its 
ability to inhibit multiple activation pathway. The combination of these effects account for a 
substantial inhibition in thrombus formation.14, 17 
We have previously reported that although PECAM-1 inhibits the activation of platelets by 
thrombin, it does not inhibit activation stimulated by TRAP. Here we investigate this disparity 
and show that the activation of PECAM-1 triggers the internalisation of GPIb by dual 
AKT/GSK-3/dynamin and αIIbβ3-dependent mechanisms, which result in the reduction in 
platelet binding of, and hence response to, thrombin, and reduced platelet binding to VWF. 
 
Materials and methods 
Materials and Methods are available in the online-only Data Supplement 
 
Results 
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Activation of PECAM-1 inhibits the binding of thrombin to human platelets and their 
subsequent activation. 
Consistent with our previous work, activating PECAM-1 by cross-linking antibodies that 
recognise the sixth Ig domain of PECAM-1 (AB468), resulting in PECAM-1 
phosphorylation,12-14 led to a small (5-15%) but significant inhibition in platelet fibrinogen 
binding and P-selectin exposure in response to thrombin across a range of concentration 
(p<0.0001 and p=0.001, respectively, two-way ANOVA) (Figure 1A).  Again confirming our 
previous findings PECAM-1 cross-linking did not inhibit platelet response to either PAR-1 or 
PAR-4 activating peptides (Figure 1A). The inhibition of thrombin activation of platelets 
without inhibiting PAR signalling suggests a role for PECAM-1 in modulating the binding of 
thrombin to platelets.  Consistent with this cross-linking PECAM-1 led to a significant 
reduction in the binding to FITC-labelled thrombin and a concomitant reduction of platelet 
activation measured by the surface exposure of P-selectin (Figure 1B and Supplementary 
Figure I).   
This reduction of thrombin binding was specific to the activation of PECAM-1. To control for 
the potential steric inhibition caused by the binding and cross-linking of the PECAM-1 
antibody we repeated these experiment using a different PECAM-1 antibody (WM59) that 
binds PECAM-1 but prevents its activation, thereby providing a control for any steric effects. 
No reduction in thrombin binding was seen when platelets were incubated with antibodies 
against the 1st or 2nd Ig domain of PECAM-1 (WM59) (which prevent homophilic ligation 
and the activation of PECAM-118) and the cross-linking antibody (Figure 1C).  Similarly the 
binding and cross-linking of antibodies against GPIbα, GPVI, PAR-1 and PAR-4 had no 
effect on the binding of thrombin to the platelet surface (Figure 1C).  
PECAM-1 crosslinking reduces the levels of GPIbα at the cell surface.  
GPIbα as part of the GPIb/V/IX complex plays an integral role in thrombin activation.  It is a 
high affinity receptor for thrombin19 and acts as a cofactor for PAR cleavage.20  Furthermore 
PECAM-1 plays a role in GPIb signalling, becoming tyrosine phosphorylated upon VWF 
binding to GPIbα, and PECAM-1 deficient mice show enhanced aggregation in response to 
VWF.9  We hypothesised that the reduction in thrombin binding to platelets may be due to 
reduced surface expression of GPIbα following PECAM-1 activation.  PECAM-1 cross-linking 
resulted in a significant reduction in the binding of antibodies against GPIbα, and a reduction 
in antibodies against GPIbβ (Figure 2A and Supplementary Figure II).  Although the level of 
GPIbα expressed on the surface of resting platelets varied between subjects the reduction in 
GPIbα following PECAM-1 cross-linking occurred in all subjects. The action of PECAM-1 
appeared to be specific for GPIb and did not cause a reduction in the binding of antibodies 
against PAR-1 and PAR-4, nor GPVI (Figure 2A).   
To confirm that this reduction was due to PECAM-1, PECAM-1 on the surface of WT mouse 
platelets was cross-linked using antibodies that recognise the sixth Ig domain of mouse 
PECAM-1 (M-185), and, as with human blood resulted in a significant decrease in GPIbα on 
the platelet surface.  No such decrease was seen in PECAM-1 deficient mouse platelets 
(Figure 2B).  Again to control for the effects of steric inhibitions caused by the binding and 
cross-linking of the PECAM-1 antibody we repeated these experiments using a different 
PECAM-1 antibody (WM59) that binds PECAM-1 but prevents its activation.  No reduction in 
GPIbα was seen when platelets were incubated with antibodies against the 1st or 2nd Ig 
domain of PECAM-1 (WM59) and the cross-linking antibody (Figure 2C).   
PECAM-1 activation inhibits platelet binding to VWF  
Given these findings we hypothesised that PECAM-1 cross-linking should also reduce 
platelet adhesion to VWF.  The number of platelets in whole blood binding to VWF 
(100μg/ml) under arterial flow conditions was indeed reduced following PECAM-1 cross-
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linking (Figure 2D-G). This supports the role of PECAM-1 in regulating surface GPIbα and is 
in line with previous reports showing enhanced aggregation in response to VWF in PECAM-1 
deficient mice.9 
PECAM-1 mediated reduction of platelet surface GPIbα is due to internalisation and not 
cleavage. 
We sought to determine if the PECAM-1 mediated reduction in the surface expression of 
GPIbα was due to internalisation or cleavage of the receptor.  Previous reports have 
demonstrated the cleavage of GPIbα by ADAM17, generating a ~95kDa fragment and a 
~45kDa N-terminal fragment.21  Using a purified cobra metalloproteinase, Nk (10μg/mL)22 as 
a positive control we identified both the ~130kDa intact GPIbα and the ~95kDa and ~45kDa 
fragments by Western blotting, using antibodies against the C-terminal and N-terminal of 
GPIbα respectively (Figure 3A).  Neither of these cleaved forms of GPIbα were observed in 
lysates of resting, CRP-XL stimulated or PECAM-1 stimulated platelets, indicating that no 
detectable cleavage of GPIbα occurred (Figure 3A). Furthermore, there was no evidence of 
any GPIbα cleavage products in these samples. Although there is a smear in the lane of the 
PECAM-1 stimulated platelets, this appears at the same height when probing with both the 
N-terminal and C-terminal antibodies and is present in the antibody control lanes. We 
therefore conclude that this smear is not due to cleavage of GPIbα. 
To further test if GPIbα was cleaved or internalised we measured the binding of GPIbα 
antibodies to non-permeablised and permeablised platelets.  As in all previous experiments 
the binding of GPIbα antibodies to non-permeablised platelets (i.e. binding solely to GPIbα 
expressed on the surface of platelets) decreased following PECAM-1 stimulation. There was, 
however, no reduction in binding of GPIbα antibodies to permeablised platelets (i.e. when 
the GPIb antibody could access both external and internal pools of GPIb) indicating that 
there was no loss of GPIbα from the platelets (Figure 3B). Taken together these two pieces 
of evidence suggest that PECAM-1 mediated reduction of platelet surface GPIbα is due to 
internalisation and not cleavage. 
PECAM-1 internalisation of GPIbα is dependent on cytoskeletal rearrangement and 
exogenous calcium ions. 
The internalisation of GPIbα is well known following platelet activation,23 and PECAM-1 has, 
in other cells types, been shown to be involved in non-clathrin mediated endocytosis.24  To 
elucidate the mechanism by which PECAM-1 mediated internalisation (PMI) of GPIbα occurs 
in platelets the reduction in surface expression of GPIbα was measured following PECAM-1 
activation in the presence of EGTA, to chelate extracellular calcium ions, and/or 
Cytochalasin D and Latruculin, to prevent actin polymerisation.  Individually none of the 
compounds significantly inhibited PMI of GPIbα.  A combination of EGTA and either 
Cytochalasin D or Latrunculin did, however, completely abrogate the effect of PECAM-1 
activation on the surface expression of GPIbα (Figure 4A). By contrast GPIbα internalisation 
following stimulation of GPVI by CRP-XL was not inhibited by EGTA alone but was 
completely inhibited by either Cytochalasin D or Latrunculin (Figure 4B).  This indicates that 
while GPVI mediated internalisation of GPIbα is entirely dependent on cytoskeletal re-
arrangement, the activation of PECAM-1 initiates two separate mechanisms, one dependent 
on cytoskeleton and the other dependent on exogenous divalent cations, both of which are 
capable of modulating the surface exposure of GPIbα independently.   
Chelating extracellular calcium inhibits the activation of integrin αIIbβ3, the activation of 
which is known to be enhanced by PECAM-1.15, 25  To establish whether integrin αIIbβ3 is 
involved in PMI of GPIbα, we used knock-in (KI) mice (DiYF mice) in which tyrosines 747 
and 759 of the cytoplasmic tail of the β3 integrin were mutated to phenylalanine, preventing 
tyrosine phosphorylation, and selectively impairing outside-in αIIbβ3 signalling.26 
Internalisation of GPIbα following PECAM-1 cross-linking was reduced in heterozygous mice 
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and abolished in KI mice (Figure 4C).  In corroboration of our findings in humans, 
internalisation of GPIbα following stimulation with CRP-XL was unaltered in DiYF mice 
(Figure4D).  There was no significant difference between WT, heterozygous or homozygous 
KI mice in the surface expression of either αIIbβ3 or GPVI (Figure 4E, F).   
PMI of GPIbα occurs in an AKT/GSK-3/Dynamin dependent manner 
PECAM-1 clustering has been reported to induce Dynamin-2 dependent endocytosis in 
endothelial cells,24, 27 while in platelets dynamin has been shown to be critical to the 
internalisation of both P2Y1 and P2Y12.28 To investigate the role of dynamin in PMI of GPIbα, 
platelets were incubated with Dynasore (100μM) prior to antibody mediated PECAM-1 cross-
linking. PMI of GPIbα was reduced in the presence of Dynasore and almost abolished in the 
presence of Dynasore and EGTA (Figure 5A). In part the action of dynamin in endocytosis is 
regulated by the de-phosphorylation (by calcineurin29, 30) and re-phosphorylation (by cdk5 
and GSK-331, 32) of two serine residues in the C-terminal proline-rich domain (PRD) of 
dynamin. While de-phosphorylation of dynamin is required for clathrin-mediated endocytosis 
in neurons, non-clathrin-mediated bulk endocytosis (of the type previously shown to result 
from PECAM-1 activation in endothelial cells24) requires both de-phosphorylation and re-
phosphorylation.32, 33 We have previously shown that PECAM-1 crosslinking resulted in 
reduced phosphorylation of AKT at Ser473.12 This should lead to a reduction in the 
phosphorylation of GSK-3, which would in turn regulate its kinase activity.  Following 
stimulation of platelets with CRP-XL the phosphorylation of GSK-3β Ser9 increased 
compared to the level in unstimulated cells, however, following PECAM-1 crosslinking the 
phosphorylation of GSK3-β Ser9 decreased (Figure 5B-C).  Interestingly the same pattern 
was not repeated for GSK-3α. Ser21 phosphorylation of GSK-3α did not increase significantly 
in response to CRP-XL but did increase significantly following PECAM-1 crosslinking (Figure 
5B-C).    To confirm the role of GSK-3 in PMI we used the highly selective inhibitor of both 
GSK-3 isoforms, CHIR99021, which inhibited the internalisation of GPIbα following the 
cross-linking of PECAM-1 (Figure 5D).  Together this data suggests that the internalisation of 
GPIbα following PECAM-1 stimulation occurs in a non-clathrin, AKT/GSK-3/Dynamin 
dependant manner which may be similar to bulk endocytosis reported in endothelial or 
neuronal cells. 
 
Discussion  
Two of the enduring questions surrounding the role of PECAM-1 in regulating platelet 
response are how this ITIM containing molecule inhibits non-immunoreceptor signalling, and 
how a molecule with what appears to be a moderate impact on individual signalling pathways 
can have such a profound effect on thrombus formation in vitro and in vivo.14, 17  By 
investigating the disparity between the action of PECAM-1 on platelet response to thrombin 
and TRAP we have identified a PECAM-1 mediated receptor internalisation pathway 
mediated via dual AKT/GSK-3/Dynamin and αIIbβ3 dependent mechanisms that result in the 
internalisation of GPIbα, a reduction in thrombin binding to, and activation of, platelets and 
reduced platelet binding to VWF.  The physiological impact of PMI of GPIbα on the binding of 
platelets to vessel-bound VWF is uncertain as it is unlikely that PECAM-1 is activated before 
platelets bind to VWF and adhere to the site of vessel damage.  This novel role for PECAM-1 
in platelets does, however, explain how PECAM-1 inhibits GPCR-mediated activation of 
platelets by thrombin, and why it has such a potent impact on thrombosis. By simultaneously 
reducing thrombin stimulation through PMI of GPIb, and GPVI signalling through its action as 
an ITIM containing receptor, PECAM-1 directly regulates two of the major pathways by which 
platelets become activated and propagate thrombus formation.  
PMI of GPIbα appears to occur via a distinct mechanism that is separate from the 
internalisation of GPIbα that follows GPVI stimulation. This was seen in the internalisation of 
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GPIbα in response to CRP-XL in PECAM-1 KO mice, and the ability of Cytochalasin D and 
Latrunculin alone to inhibit CRP-XL mediated internalisation of GPIbα, but not PMI.  It is 
likely, however, that in vivo these two mechanisms work in concert, particularly as PECAM-1 
becomes phosphorylated following GPVI stimulation, and as PECAM-1 and GPVI have 
opposing effects on AKT and hence GSK-3 phosphorylation.  Why such opposing signalling 
events result in such similar outcomes is not yet known.  The importance of PMI during 
thrombus formation may in part come from the activation of PECAM-1 by homophilic ligation, 
which only occurs during close platelet-platelet contact.  Under these circumstances 
stimulation of receptor internalisation or endocytosis by PECAM-1 at the site of contact may 
be a mechanism for recycling receptors that are not occupied or bound into focal adhesion 
complexes.  Trafficking these receptors away from the site of contact to areas of the platelet 
that are not in contact with other cells provides an attractive mechanism by which to 
maximise the efficiency of platelet response to multiple simultaneous stimuli and orchestrate 
thrombus growth. 
The mechanism by which integrin β3 regulates PMI is as yet unknown.  Its effect, however, 
appears to be critical. One explanation for this, perhaps lies with filamin.  Filamin binds to 
GPIbα in resting platelets anchoring it to the cytoskeleton,34 helping to maintain the structure 
and integrity of the plasma membrane following platelet tethering to VWF under high shear.35  
Upon stimulation filamin becomes detached from the cytoplasmic tail GPIbα allowing its 
translocation.36  By contrast filamin binds to αIIbβ3 following platelet activation.  One 
tempting hypothesis is that PECAM-1 plays a role, either directly or indirectly, in the 
decoupling of filamin from GPIbα and its subsequent binding to integrin β3.  We have as yet 
been unable to confirm or refute this hypothesis but it will be the focus of future work. 
Of the two isoforms of GSK-3 it is the β form that is thought to be predominant in platelets.37 
Proteomic analysis has, however, identified that the copy number per platelet for each 
isoform is similar, 1300 for GSK-3β and 1000 for GSK-3α.38  Both isoforms are constitutively 
active in resting platelets but are inhibited by phosphorylation of Ser21 (GSK-3α) or Ser9 
(GSK-3β) by PKC or AKT upon platelet stimulation.39  It is thought that GSK-3 acts as a 
negative regulator of platelets; GSK-3 inhibitors increase platelet responses, GSK-3β +/- 
mice display increased aggregation and thrombus formation, and platelets from mice in 
which GSK-3α Ser21 and GSK-3β Ser9 have been mutated to Ala show reduced response.37, 
39  The reduction on GSK-3β pSer9 following PECAM-1 cross-linking fits with this 
understanding of platelet GSK-3. PECAM-1, which has a well-established inhibitory effect on 
platelet signalling, reduces AKT phosphorylation and therefore reduces the phosphorylation 
and inhibition GSK-3β, thereby enhancing its inhibitory effect, some of which may be 
mediated through Dynamin and translocation of surface receptors, as we have shown to be 
the case with GPIb.  The increase in GSK-3α phosphorylation following PECAM-1 cross-
linking does not, however, fit with our current understanding.  Part of the reason for this is 
that all previous work on GSK-3 in platelets has focused either on GSK-3β alone, as in the 
case of the GSK-3β +/- mice, or has assumed that both isoforms work in a similar way and 
have therefore inhibited both isoforms.  In the case of dual inhibition the effect of GSK-3α 
may be masked by GSK-3β making any interpretation of the physiological relevance of GSK-
3α impossible.  Although there is 85% similarity in the amino acid sequence between the 
isoforms and 98% homology in the kinase domain40 there is growing evidence that the two 
isoforms of GSK-3 have distinct roles.41-43  Quite why the activation of PECAM-1 has such 
contrasting effects on the two GSK-3 isoforms and what significance GSK-3α 
phosphorylation has in PECAM-1 signalling are as yet unknown.  
The inhibition of platelet activation by PECAM-1 is well known but the mechanisms by which 
this ITIM-containing receptor inhibits platelet response to thrombin were not.  Here we have 
shown that the activation of PECAM-1 results in the internalisation of GPIb by dual GSK-
3/Dynamin and αIIbβ3 dependent mechanisms, which result in the reduction in platelet 
binding of, and hence response to, thrombin, and reduced platelet binding to VWF. 
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Furthermore, we have for the first time shown the differential regulation of GSK-3α/β by 
PECAM-1 in platelets.  This novel role for PECAM-1 expands our understanding of how this 
promiscuous molecule regulates multiple diverse signalling pathways and why it has such a 
potent impact on thrombosis.  It may also suggest a role for PECAM-1 in regulating 
conditions where the generation of thrombin, and the response of platelets to thrombin is 
central to pathology.  
 
Sources of Funding 
This study was supported by British Heart Foundation grants to J.M.G. (RG/05/007, 
RG/09/011 and FS/07/018).  
Disclosures 
None. 
 
 
  
8 
 
References 
1. Newman PJ. The role of pecam-1 in vascular cell biology. Ann N Y Acad Sci. 1994;714:165-174 
2. Wu XW, Lian EC. Binding properties and inhibition of platelet aggregation by a monoclonal 
antibody to cd31 (pecam-1). Arterioscler Thromb Vasc Biol. 1997;17:3154-3158 
3. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Biochemical characterization of pecam-
1 (cd31 antigen) on human platelets. Thromb Haemost. 1991;66:700-707 
4. Jackson DE, Kupcho KR, Newman PJ. Characterization of phosphotyrosine binding motifs in 
the cytoplasmic domain of platelet/endothelial cell adhesion molecule-1 (pecam-1) that are 
required for the cellular association and activation of the protein-tyrosine phosphatase, shp-
2. J. Biol. Chem. 1997;272:24868-24875 
5. Vivier E, Daeron M. Immunoreceptor tyrosine-based inhibitory motifs. Immunol. Today. 
1997;18:286-291 
6. Cao MY, Huber M, Beauchemin N, Famiglietti J, Albelda SM, Veillette A. Regulation of mouse 
pecam-1 tyrosine phosphorylation by the src and csk families of protein-tyrosine kinases. The 
Journal of biological chemistry. 1998;273:15765-15772 
7. Cicmil M, Thomas JM, Sage T, Barry FA, Leduc M, Bon C, Gibbins JM. Collagen, convulxin, and 
thrombin stimulate aggregation-independent tyrosine phosphorylation of cd31 in platelets. 
Evidence for the involvement of src family kinases. J. Biol. Chem. 2000;275:27339-27347 
8. Jackson DE, Ward CM, Wang R, Newman PJ. The protein-tyrosine phosphatase shp-2 binds 
platelet/endothelial cell adhesion molecule-1 (pecam-1) and forms a distinct signaling 
complex during platelet aggregation. J. Biol. Chem. 1997;272:6986-6993 
9. Rathore V, Stapleton MA, Hillery CA, Montgomery RR, Nichols TC, Merricks EP, Newman DK, 
Newman PJ. Pecam-1 negatively regulates gpib/v/ix signaling in murine platelets. Blood. 
2003;102:3658-3664 
10. Jones KL, Hughan SC, Dopheide SM, Farndale RW, Jackson SP, Jackson DE. Platelet 
endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. 
Blood. 2001;98:1456-1463 
11. Hua CT, Gamble JR, Vadas MA, Jackson DE. Recruitment and activation of shp-1 protein-
tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (pecam-1). 
Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and 
substrates. J. Biol. Chem. 1998;273:28332-28340 
12. Moraes LA, Barrett NE, Jones CI, Holbrook LM, Spyridon M, Sage T, Newman DK, Gibbins JM. 
Pecam-1 regulates collagen-stimulated platelet function by modulating the association of pi3 
kinase with gab1 and lat. J Thromb Haemost. 2010;8:2530-2541 
13. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. Pecam-1 signalling inhibits the activation 
of human platelets. Blood. 2002;99:137-144 
14. Jones CI, Garner SF, Moraes LA, Kaiser WJ, Rankin A, Ouwehand WH, Goodall AH, Gibbins JM. 
Pecam-1 expression and activity negatively regulate multiple platelet signaling pathways. 
FEBS Lett. 2009;583:3618-3624 
15. Wee JL, Jackson DE. The ig-itim superfamily member pecam-1 regulates the "outside-in" 
signaling properties of integrin alpha(iib)beta(3) in platelets. Blood. 2005;106:3816-3823 
16. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, 
tissue factor and fibrin during arterial thrombus formation in the mouse. Nature medicine. 
2002;8:1175-1181 
17. Falati S, Patil S., Gross PL, Stapleton M, Merrill-Skoloff G., Barrett NE, Pixton KL, Weiler H., 
Cooley B., Newman D.K., Newman PJ, Furie BC, Furie B., Gibbins JM. Platelet pecam-1 
inhibits thrombus formation in vivo. Blood. 2006;107:535-541 
18. Sun QH, DeLisser HM, Zukowski MM, Paddock C, Albelda SM, Newman PJ. Individually 
distinct ig homology domains in pecam-1 regulate homophilic binding and modulate 
receptor affinity. The Journal of biological chemistry. 1996;271:11090-11098 
9 
 
19. Buchanan SG, Gay NJ. Structural and functional diversity in the leucine-rich repeat family of 
proteins. Progress in Biophysics and Molecular Biology. 1996;65:1-44 
20. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin 
to glycoprotein ib accelerates the hydrolysis of par-1 on intact platelets. The Journal of 
biological chemistry. 2001;276:4692-4698 
21. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding 
of platelet glycoprotein (gp)vi and gpib-ix-v by adam family metalloproteinases. J Thromb 
Haemost. 2007;5:1530-1537 
22. Wijeyewickrema LC, Gardiner EE, Shen Y, Berndt MC, Andrews RK. Fractionation of snake 
venom metalloproteinases by metal ion affinity: A purified cobra metalloproteinase, nk, from 
naja kaouthia binds ni2+-agarose. Toxicon : official journal of the International Society on 
Toxinology. 2007;50:1064-1072 
23. Han Y, Nurden A, Combrie R, Pasquet JM. Redistribution of glycoprotein ib within platelets in 
response to protease-activated receptors 1 and 4: Roles of cytoskeleton and calcium. J 
Thromb Haemost. 2003;1:2206-2215 
24. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M. A novel 
endocytic pathway induced by clustering endothelial icam-1 or pecam-1. Journal of cell 
science. 2003;116:1599-1609 
25. Varon D, Jackson DE, Shenkman B, Dardik R, Tamarin I, Savion N, Newman PJ. 
Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that 
modulates integrin-dependent adhesion and aggregation of human platelets. Blood. 
1998;91:500-507 
26. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin 
cytoplasmic tyrosine motif is required for outside-in alphaiibbeta3 signalling and platelet 
function. Nature. 1999;401:808-811 
27. Garnacho C, Shuvaev V, Thomas A, McKenna L, Sun J, Koval M, Albelda S, Muzykantov V, 
Muro S. Rhoa activation and actin reorganization involved in endothelial cam-mediated 
endocytosis of anti-pecam carriers: Critical role for tyrosine 686 in the cytoplasmic tail of 
pecam-1. Blood. 2008;111:3024-3033 
28. Mundell SJ, Barton JF, Mayo-Martin MB, Hardy AR, Poole AW. Rapid resensitization of 
purinergic receptor function in human platelets. J Thromb Haemost. 2008;6:1393-1404 
29. Liu JP, Sim AT, Robinson PJ. Calcineurin inhibition of dynamin i gtpase activity coupled to 
nerve terminal depolarization. Science. 1994;265:970-973 
30. Marks B, McMahon HT. Calcium triggers calcineurin-dependent synaptic vesicle recycling in 
mammalian nerve terminals. Current biology : CB. 1998;8:740-749 
31. Clayton EL, Sue N, Smillie KJ, O'Leary T, Bache N, Cheung G, Cole AR, Wyllie DJ, Sutherland C, 
Robinson PJ, Cousin MA. Dynamin i phosphorylation by gsk3 controls activity-dependent bulk 
endocytosis of synaptic vesicles. Nature neuroscience. 2010;13:845-851 
32. Tan TC, Valova VA, Malladi CS, Graham ME, Berven LA, Jupp OJ, Hansra G, McClure SJ, 
Sarcevic B, Boadle RA, Larsen MR, Cousin MA, Robinson PJ. Cdk5 is essential for synaptic 
vesicle endocytosis. Nature cell biology. 2003;5:701-710 
33. Clayton EL, Anggono V, Smillie KJ, Chau N, Robinson PJ, Cousin MA. The phospho-dependent 
dynamin-syndapin interaction triggers activity-dependent bulk endocytosis of synaptic 
vesicles. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
2009;29:7706-7717 
34. Andrews RK, Fox JE. Identification of a region in the cytoplasmic domain of the platelet 
membrane glycoprotein ib-ix complex that binds to purified actin-binding protein. The 
Journal of biological chemistry. 1992;267:18605-18611 
35. Cranmer SL, Ashworth KJ, Yao Y, Berndt MC, Ruggeri ZM, Andrews RK, Jackson SP. High 
shear-dependent loss of membrane integrity and defective platelet adhesion following 
disruption of the gpibalpha-filamin interaction. Blood. 2011;117:2718-2727 
10 
 
36. Dyson JM, Munday AD, Kong AM, Huysmans RD, Matzaris M, Layton MJ, Nandurkar HH, 
Berndt MC, Mitchell CA. Ship-2 forms a tetrameric complex with filamin, actin, and gpib-ix-v: 
Localization of ship-2 to the activated platelet actin cytoskeleton. Blood. 2003;102:940-948 
37. Li D, August S, Woulfe DS. Gsk3beta is a negative regulator of platelet function and 
thrombosis. Blood. 2008;111:3522-3530 
38. Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, 
Zahedi RP. The first comprehensive and quantitative analysis of human platelet protein 
composition allows the comparative analysis of structural and functional pathways. Blood. 
2012;120:e73-82 
39. Moore SF, van den Bosch MT, Hunter RW, Sakamoto K, Poole AW, Hers I. Dual regulation of 
glycogen synthase kinase 3 (gsk3)alpha/beta by protein kinase c (pkc)alpha and akt promotes 
thrombin-mediated integrin alphaiibbeta3 activation and granule secretion in platelets. The 
Journal of biological chemistry. 2013;288:3918-3928 
40. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor a. The 
EMBO journal. 1990;9:2431-2438 
41. Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, Urbanska M, Jaworski J, Pietrokovski S, 
Hirschberg K, Eldar-Finkelman H. Distinct molecular regulation of glycogen synthase kinase-
3alpha isozyme controlled by its n-terminal region: Functional role in calcium/calpain 
signaling. The Journal of biological chemistry. 2011;286:13470-13480 
42. Ciaraldi TP, Nikoulina SE, Bandukwala RA, Carter L, Henry RR. Role of glycogen synthase 
kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology. 
2007;148:4393-4399 
43. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen 
synthase kinase-3beta in cell survival and nf-kappab activation. Nature. 2000;406:86-90 
  
11 
 
Significance. 
We show two new facets of PECAM-1 biology in platelets.  1) That PECAM-1 mediates the 
internalisation of GPIbα leading to a reduction in the activation of platelets by thrombin and a 
reduction in their binding to VWF. 2) That PECAM-1 differentially regulates the 
phosphorylation of the two isoforms of GSK-3.  In so doing this article answers a number of 
the outstanding questions concerning the regulation of platelets by PECAM-1; how this ITIM 
containing molecule inhibits non-immunoreceptor signalling, and importantly, how PECAM-1 
has such a profound effect on thrombus formation in vitro and in vivo. 
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Figure 1 – Activation of PECAM-1 inhibits the binding of thrombin to human platelets 
and their subsequent activation.  (A) Fibrinogen binding (top row) and P-selectin 
expression (bottom row) to human platelets in response to thrombin, PAR-1 or PAR-4 
activating peptides in the presence (black) or absence (grey) of PECAM-1 (AB468) 
crosslinking and activation was measured by flow cytometry (n=5).  P-values compare the 
difference between the two curves over the entire concentration range using Two-way 
ANOVA with Bonferroni post-test analysis of the difference at individual concentrations. (B) 
To ascertain if reduced platelet response to thrombin was due to reduced thrombin binding, 
the reduction in the binding of FITC-labelled thrombin to human platelets (left) and the 
resultant surface exposure of P-selectin (right) was measured following PECAM-1 
crosslinking. The binding of FITC-thrombin to platelets was measured by flow cytometry and 
is presented as the median fluorescent intensity (MFI) (left hand axis - presence (black line) 
or absence (grey line) of PECAM-1 (AB468) crosslinking) and the percentage reduction in 
median fluorescent intensity (MFI) in PECAM-1 cross-linked samples compared to the 
isotype control (right hand axis) (n=5). (C) To check that this reduction in thrombin binding 
was specific to the activation of PECAM-1 and not the binding of antibodies to the platelet 
surface, the binding of FITC labelled thrombin to human platelets in the presence of cross-
linked isotype control, PECAM-1 (WM59 - inhibitory), GPIbα, GPVI, PAR-1 or PAR-4 
antibodies was measured (n=3). In all cases *p<0.05, **p=<0.01, ***p<0.001. 
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Figure 2 – Activation of PECAM-1 reduces the surface expression of GPIbα and 
reduces platelet binding to vWF.  (A) Human platelet surface expression of GPIbα, GPIbβ, 
GPVI, PAR-1, PAR-4 in the presence (black) or absence (grey) of PECAM-1 (AB468) 
crosslinking was measured by flow cytometry (n=12 for anti-GPIbα, and n=3 for all other 
experiments).  (B) To confirm that this was PECAM-1 specific the expression of GPIbα on 
the surface of mouse platelets from WT (n=4) or PECAM-1 KO (n=6) mice following the 
crosslinking of isotype control (grey) or PECAM-1 stimulatory antibodies (black) was 
measured. (C) To check that this reduction in the surface of GPIbα was specific to the 
activation of PECAM-1 and not the binding of antibodies to the platelet surface, human 
platelet surface expression of GPIbα was measured in the presence of cross-linked isotype 
control (grey), PECAM-1 (WM59 - inhibitory)(black)(n=4). The difference in MFI between (A) 
and (C) are because they were performed on different flow cytometers, a FACSCalibur and 
an Accuri C6, respectively. (D-G) Given the importance of GPIbα in platelet tethering to VWF 
we assessed the impact of PECAM-1 crosslinking on the binding of platelets to VWF under 
flow. (D) Representative images showing human platelets binding to VWF (100μg/ml) under 
flow conditions following the crosslinking of isotype control or PECAM-1 stimulatory 
antibodies, or, as a positive control, antibodies that block the binding of GPIb to VWF 
(Haematologic Technologies Inc). (E) The number of human platelets binding to VWF 
(100μg/ml), (F) the area covered by, and (G) the sum fluorescence intensity of these 
platelets following the crosslinking of isotype control (grey) or PECAM-1 (black) stimulatory 
antibodies (n=3). *p<0.05, **p=<0.01, ***p<0.001 
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Figure 3 – GPIbα is internalised and not cleaved following PECAM-1 activation. (A) To 
determine whether GPIbα is cleaved following PECAM-1 activation, human platelets that had 
been stimulated for 90 or 600 seconds with CRP-XL (μg/mL), or undergone PECAM-1 
activation via antibody crosslinking, or been exposed to purified cobra metalloproteinase, Nk 
(10μg/ml), were probed by western blotting using antibodies that recognise either the C or 
the N-terminal domain of GPIbα.  Cleavage products were clearly visible in samples treated 
with Nk but not CRP-XL or PECAM-1 stimulated platelets.  The smear present in the 
PECAM-1 stimulated samples appears at the same height when probing with both the N-
terminal and C-terminal antibodies and appears when the antibodies are run alone in the 
absence of platelets. We therefore conclude that it is the result of protein in the stimulating 
antibodies rather than a result of cleavage.  (B) To identify the internalisation of GPIbα 
following PECAM-1 activation the binding of GPIbα antibodies to non-permeablised human 
platelets (i.e. binding to GPIbα expressed on the surface of platelets) or to permeablised 
platelets (i.e. binding to all GPIbα, internal and surface expressed) following PECAM-1 
cross-linking was measured by flow cytometery (n=3). *p<0.05. 
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Figure 4 – Actin polymerisation and αIIbβ3 are required for PECAM-1 mediated 
internalisation of GPIbα.  Surface expression of GPIbα on human platelets following (A) 
PECAM-1 crosslinking or (B) stimulation with CRP-XL in the presence of EGTA (2mM), 
Cytochalasin D (50μM) or Latrunculin (8.5μM) was measured by flow cytometry (n=5).  To 
test the involvement of αIIbβ3 in PMI of GPIbα, platelets from DiYF mice, in which tyrosines 
747 and 759 of the cytoplasmic tail of the β3 integrin were mutated to phenylalanine, 
underwent (C) PECAM-1 crosslinking or (D) CRP-XL stimulation followed by measurement 
of surface GPIbα.  The surface expression of (E) αIIbβ3 and (F) GPVI were also measured in 
these mice and showed no significant difference between the genotypes in resting or CRP-
XL stimulated conditions (WT: n=5, Het: n=9, KI: n=5). Asterisks indicate significant 
difference from isotype control or resting platelets in all cases. *p<0.05, **p=<0.01, 
***p<0.001
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Figure 5 – PECAM-1 mediated internalisation of GPIbα is dependent on AKT/GSK-
3/Dynamin signalling.  (A) The reduction in the expression of GPIbα on the platelet surface 
resulting from PECAM-1 crosslinking was measured in the absence or presence of Dynasore 
(100μM) or Dynasore and EGTA together (n=8). (B) A representative image showing 
phosphorylation of GSK-3α Ser21 and GSK-3β Ser9, and total GSK-3α and β following 
platelet stimulation by CRP-XL (1μg/mL) or PECAM-1 cross-linking.  (C) Quantification of 
Western blots showing phosphorylation of GSK-3α Ser21 and GSK-3β Ser9, and total GSK-3α 
and β following platelet stimulation by CRP-XL (1μg/mL) or PECAM-1 cross-linking (n=3). (D) 
The reduction in the expression of GPIbα on the platelet surface resulting from PECAM-1 
cross-linking was measured in the absence or presence of the GSK-3 inhibitor CHIR99021 
(3μM), or CHIR99021 (3μM) and EGTA (2mM) together (n=3). *p<0.05, **p=<0.01, ***p<0.001 
 
 
 
 
 
